Why Merchant Center Suspends Peptide Stores: The 6 Triggers to Check First

Why does Merchant Center suspend peptide stores?

Merchant Center suspends peptide stores when the site, the product data or the business behind them breaks a specific Shopping policy — most often Misrepresentation, Healthcare and medicines (unapproved pharmaceuticals and supplements, or prescription drugs), missing policies and contact details, feed-to-site mismatches, or attempts to get around review. “Peptide” is not itself a suspension reason. The named policy in your notice is the single most important fact you have, because each one has a different fix and a different recovery path.

Operators tend to read a suspension as a verdict on their industry. It is almost never that simple. Google reviews information from your products, your website, your accounts and third-party sources, and it applies several overlapping policies at once. Two stores selling the same catalogue can land in completely different places because one describes its products as laboratory reagents and the other describes what they do to a human body.

How do you tell which policy you actually hit?

Read the notice before you touch the site. The account issue banner and the “Needs attention” tab name a policy, and that name maps to one of six trigger families. The table below is ordered by severity rather than frequency — we have not published a counted frequency ranking, and we would treat anyone who quotes one without a dataset with caution.

Trigger	What the notice usually names	Warning first?	Where the fix lives
1. Business misrepresentation	Misrepresentation	No — Google states suspension is upon detection	Entity, identity, claims, trust signals
2. Unapproved substances	Healthcare and medicines — unapproved pharmaceuticals and supplements	Usually 7 or 28 days; not for egregious cases	Product pages, catalogue scope, claims
3. Prescription drug terms	Healthcare and medicines — prescription drugs	Usually 7 or 28 days	Feed titles, product names, certification
4. Missing policies and contact data	Website needs improvement, insufficient contact information, missing return and refund policy	Usually	Footer, policy pages, business info settings
5. Feed-to-site mismatch	Price or availability mismatch; unavailable offers	Item-level first, can escalate	Feed pipeline, landing pages
6. Circumventing review	Abuse of the network; linked account suspension	Often no	Account history, crawler access, other accounts

Warning periods and review times come from Google’s own help pages: most healthcare violations get a warning email with 7 or 28 calendar days to fix, you can request one courtesy review during that window, and account reviews typically take up to 7 business days. Egregious violations can skip the warning entirely.

What are the six triggers, and what does each one look like on a peptide site?

1. Misrepresentation of the business

Google’s Misrepresentation policy covers hiding or misstating who you are, offering products you cannot lawfully deliver, implying endorsements you do not have, and omitting material information such as total cost, shipping terms or refund conditions. For peptide stores the common versions are thin or inconsistent identity (a different business name in the footer, on the payment descriptor and in Merchant Center settings), unverifiable purity or “pharmaceutical grade” claims, and borrowed authority such as lab or government imagery that implies an affiliation. Google describes Misrepresentation as egregious and says accounts are reinstated “only in compelling circumstances.” Our misrepresentation guide goes deeper.

2. Unapproved pharmaceuticals and supplements

The Shopping healthcare policy disallows anything on Google’s non-exhaustive prohibited list, and also any non-government-approved product “marketed in a way that implies that they’re safe or effective” for preventing, curing or treating a disease. Named peptides are mostly not on the published list, which leads operators to assume they are fine. The operative clause is the marketing one: copy describing what a compound does in the body is what converts a catalogue item into an unapproved-substance problem. Google also points to LegitScript for the products it monitors, and may disallow products that have been the subject of government or regulatory action or warning.

3. Prescription drug terms

Products named after approved or investigational prescription drugs — semaglutide, tirzepatide, retatrutide, tesamorelin and similar — fall under the prescription drug rules, which require certification and are only available to specific advertiser types in specific countries. A research supplier is not in that category. Renaming the product does not help: Google disallows names “confusingly similar” to prescription drugs and prohibited products, and gives examples such as misspelled brand names.

4. Missing policies and contact data

Google’s troubleshooting guidance for Misrepresentation and “Website needs improvement” is concrete: consistent legal name, physical address, phone and email across the site and Merchant Center; explicit links to shipping, refund and privacy policies; no placeholder text or broken links; a working HTTPS checkout; and identity verification with documents that match the account. These are the cheapest fixes on this list and the most often skipped.

5. Feed-to-site mismatch

Prices, availability and titles in the feed must match the landing page. Peptide stores trigger this more than most because they run frequent restocks, variant-heavy catalogues (multiple strengths per compound) and checkout-only pricing. Promoting a product that is out of stock or an offer that has ended sits inside the Misrepresentation policy’s “unavailable offers” section, so a data problem can become a trust problem. See peptide Google Shopping for feed structure.

6. Circumventing review

Google’s “Abuse of the network” policy lists cloaking, dynamic content switching, manipulating product data or site content to bypass automated checks, and restricting crawler access to landing pages. It also covers having a suspended account linked to your Merchant Center. Two peptide-specific cautions: showing Google a sanitised catalogue while customers see another is textbook cloaking, and aggressive bot protection, login walls or age gates in front of product pages are worth checking because Google’s crawlers need to reach what customers see.

Why is “research use only” not enough in 2026?

Because regulators and platforms read the whole page, not the disclaimer. On 24 August 2026 the FDA published a batch of warning letters to online peptide sellers. The letters we reviewed follow the same pattern: despite “research use only” and “not for human consumption” statements, the agency concluded the products were intended for human use based on evidence from the sellers’ own websites.

Three kinds of evidence recur in those letters, and every one of them is also a Merchant Center signal:

• Research-framed benefit copy. Phrases like “studied for effects on appetite regulation” or “explored for potential impact on body weight” were quoted as drug claims. Hedged, preclinical-sounding language still describes an effect on the body.
• Reconstitution supplies sold alongside peptides. Bacteriostatic water marketed for reconstituting products was cited as providing the means to prepare an injectable drug.
• Dosing tools. “Peptide calculators” and usage guides were cited in the same way.

The separate regulatory story — FDA removing 12 peptides from its Category 2 compounding list in April 2026, and an advisory committee in July backing six of them for possible addition to the 503A bulks list — concerns licensed compounding pharmacies. It does not make research-use consumer sales advertisable, and the FDA has not finalised any listing. Treat that news as relevant to pharmacies and telehealth, not as a green light for a Shopping catalogue.

What should you do in the first 72 hours after a suspension?

1. Freeze changes to feeds and accounts. Do not delete and re-upload the catalogue, do not open a new Merchant Center, and do not relink a different Google Ads account. Each of these can create a second problem.
2. Record the exact notice. Screenshot the account issue, the policy named, the country affected and any date. Save the emails. You will need them for the appeal narrative.
3. Map the notice to one trigger family using the table above. If more than one policy is named, list them all — a review applies to every issue for that country.
4. Check identity verification. Google notes the review button may be unavailable until identity verification is complete and your data source contains at least one product.
5. Audit before appealing. Work through the peptide site remediation checklist for the whole domain, not just flagged products. Google reviews the site as a whole.
6. Decide: fix or disagree. Merchant Center offers “I fixed the issue” and “I disagree with the issue.” Only choose disagree if you genuinely believe the finding is wrong and can evidence it.

What will the suspension notice not tell you?

The notice names a policy; it does not list every page that triggered it. Google says its review draws on your products, website, accounts and third-party sources, and its own documentation describes the examples it gives as non-exhaustive. In practice that means:

• The flagged product is a symptom, not the boundary. Old blog posts, FAQ pages, customer reviews and category descriptions are all part of the site being reviewed.
• Linked properties matter. A suspended linked Google Ads account is itself listed as a trigger under Abuse of the network.
• Off-site signals exist. Google lists adverse regulatory warnings and settlements about business practices among the situations it may act on under Misrepresentation. A public warning letter about your company is exactly that kind of signal.

Not sure where your store stands before you request a review? The Google Ads Readiness Score walks through the same categories in a few minutes, and if you want a second pair of eyes on the notice itself, book a strategy call. Nobody — including us — can promise reinstatement; what can be controlled is how complete the fix is before a review is spent.

Sources

• Google Merchant Center Help — Misrepresentation
• Google Merchant Center Help — Healthcare and medicines and Unapproved pharmaceuticals and supplements (list)
• Google Merchant Center Help — Abuse of the network
• Google Merchant Center Help — Request a review of your issues (warning periods, cool-down) and Fixing warnings and account suspensions
• U.S. FDA — Warning letter 735127, 24 August 2026 (one of several published the same day)
• Orrick — FDA removal of 12 peptides from Category 2 (April 2026)

Policies checked 23 September 2026. Google updates these pages without notice; verify against the live help centre before acting.

Frequently asked